JP2005526520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526520A5 JP2005526520A5 JP2004508299A JP2004508299A JP2005526520A5 JP 2005526520 A5 JP2005526520 A5 JP 2005526520A5 JP 2004508299 A JP2004508299 A JP 2004508299A JP 2004508299 A JP2004508299 A JP 2004508299A JP 2005526520 A5 JP2005526520 A5 JP 2005526520A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- pharmaceutical composition
- muc
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212046.7A GB0212046D0 (en) | 2002-05-24 | 2002-05-24 | Vaccines |
| PCT/EP2003/005594 WO2003100060A2 (en) | 2002-05-24 | 2003-05-23 | Muc-1 antigen with reduced number of vntr repeat units |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526520A JP2005526520A (ja) | 2005-09-08 |
| JP2005526520A5 true JP2005526520A5 (https=) | 2006-06-08 |
Family
ID=9937394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508299A Pending JP2005526520A (ja) | 2002-05-24 | 2003-05-23 | Ｖｎｔｒ反復ユニットの数が減少したｍｕｃ−１抗原 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060251665A1 (https=) |
| EP (1) | EP1527177A2 (https=) |
| JP (1) | JP2005526520A (https=) |
| KR (1) | KR20050004211A (https=) |
| CN (1) | CN100408682C (https=) |
| AR (1) | AR039846A1 (https=) |
| AU (1) | AU2003240729B2 (https=) |
| BR (1) | BR0311211A (https=) |
| CA (1) | CA2485816A1 (https=) |
| GB (1) | GB0212046D0 (https=) |
| IL (1) | IL165156A0 (https=) |
| IS (1) | IS7526A (https=) |
| MX (1) | MXPA04011527A (https=) |
| NO (1) | NO20044947L (https=) |
| NZ (1) | NZ536668A (https=) |
| PL (1) | PL374569A1 (https=) |
| RU (1) | RU2303069C2 (https=) |
| TW (1) | TW200407426A (https=) |
| WO (1) | WO2003100060A2 (https=) |
| ZA (1) | ZA200409445B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| DK1694364T3 (da) * | 2003-11-12 | 2014-07-21 | Us Government | System til behandling og forebyggelse af brystcancer |
| WO2005046622A2 (en) * | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| WO2006081553A2 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | ANTI-MUC1 α/ß ANTIBODIES |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| CA2800911A1 (en) * | 2010-06-11 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | Immunogenic vaccine |
| CN106215179A (zh) * | 2010-06-11 | 2016-12-14 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
| EP2678005A4 (en) * | 2011-02-24 | 2015-06-10 | Oncothyreon Inc | GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS |
| MX2018008797A (es) * | 2016-01-19 | 2018-11-29 | Pfizer | Vacunas contra el cancer. |
| CN110198733B (zh) * | 2016-09-28 | 2024-04-30 | 巴法里安诺迪克有限公司 | 用于增强痘病毒中转基因的稳定性的组合物和方法 |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2264145T3 (es) * | 1995-11-30 | 2006-12-16 | The Board Of Regents, The University Of Texas System | Metodos y composiciones para el tratamiento de cancer. |
| CA2282300C (en) * | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6228843B1 (en) * | 1999-04-23 | 2001-05-08 | University Technology Corporation | Method of using PKC inhibiting compounds to treat vascular disease |
| CA2383737C (en) * | 1999-09-08 | 2011-01-18 | Transgene S.A. | Muc-1 derived peptides |
| GB9930359D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
| JP2003533181A (ja) * | 2000-02-01 | 2003-11-11 | ジ・オースティン・リサーチ・インスティテュート | ムチン−１誘導抗原および免疫療法におけるその使用 |
| US20020142047A1 (en) * | 2001-01-19 | 2002-10-03 | Johnson Mark E. | Microsphere delivery of mucin peptides |
| WO2002101075A2 (en) * | 2001-06-13 | 2002-12-19 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| ES2375992T3 (es) * | 2002-04-15 | 2012-03-08 | Oncothyreon Inc. | Glucolipopéptidos sintéticos como vacunas. |
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
-
2002
- 2002-05-24 GB GBGB0212046.7A patent/GB0212046D0/en not_active Ceased
-
2003
- 2003-05-22 TW TW092113870A patent/TW200407426A/zh unknown
- 2003-05-22 AR ARP030101782A patent/AR039846A1/es unknown
- 2003-05-23 CN CNB038171988A patent/CN100408682C/zh not_active Expired - Fee Related
- 2003-05-23 CA CA002485816A patent/CA2485816A1/en not_active Abandoned
- 2003-05-23 AU AU2003240729A patent/AU2003240729B2/en not_active Ceased
- 2003-05-23 MX MXPA04011527A patent/MXPA04011527A/es not_active Application Discontinuation
- 2003-05-23 WO PCT/EP2003/005594 patent/WO2003100060A2/en not_active Ceased
- 2003-05-23 PL PL03374569A patent/PL374569A1/xx unknown
- 2003-05-23 JP JP2004508299A patent/JP2005526520A/ja active Pending
- 2003-05-23 KR KR10-2004-7018958A patent/KR20050004211A/ko not_active Ceased
- 2003-05-23 RU RU2004134331/13A patent/RU2303069C2/ru active
- 2003-05-23 US US10/515,871 patent/US20060251665A1/en not_active Abandoned
- 2003-05-23 EP EP03730134A patent/EP1527177A2/en not_active Withdrawn
- 2003-05-23 BR BR0311211-0A patent/BR0311211A/pt not_active IP Right Cessation
- 2003-05-23 NZ NZ536668A patent/NZ536668A/en unknown
-
2004
- 2004-11-10 IL IL16515604A patent/IL165156A0/xx unknown
- 2004-11-11 IS IS7526A patent/IS7526A/is unknown
- 2004-11-12 NO NO20044947A patent/NO20044947L/no not_active Application Discontinuation
- 2004-11-23 ZA ZA200409445A patent/ZA200409445B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10973909B1 (en) | Coronavirus vaccine | |
| JP2005526520A5 (https=) | ||
| JP5873335B2 (ja) | フィブロネクチンｉｉｉ型ドメインに基づくスカフォールド組成物、方法及び使用 | |
| Jafari et al. | Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms | |
| JP5848607B2 (ja) | フィブロネクチン３型ドメインに基づくスカフォールド組成物、方法及び使用 | |
| JP2008508859A5 (https=) | ||
| JP2010500399A5 (https=) | ||
| JP2006512300A5 (https=) | ||
| JP2008530245A5 (https=) | ||
| HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
| JP2009292810A5 (https=) | ||
| RU2016109939A (ru) | Способ повышения экспрессии кодируемых рнк белков | |
| CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
| CA2700378A1 (en) | Nanotherapeutic colloidal metal compositions and methods | |
| JP2008056679A5 (https=) | ||
| JP2015501840A5 (https=) | ||
| JP2009515831A5 (https=) | ||
| JP2004513622A5 (https=) | ||
| JP2008507536A5 (https=) | ||
| JP2016513115A5 (https=) | ||
| JP2003530088A5 (https=) | ||
| RU2004134331A (ru) | Антиген muc1 со сниженным числом повторяющихся vntr-блоков | |
| JP2011517938A5 (https=) | ||
| JP2019531293A5 (https=) | ||
| JP2006506942A5 (https=) |